<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A new immunoglobulin (Ig) for intravenous use was given in high doses to 4 children with refractory <z:hpo ids='HP_0001973'>idiopathic thrombocytopenic purpura</z:hpo> (<z:chebi fb="0" ids="16039">ITP</z:chebi>) and 2 children with idiopathic <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (<z:mp ids='MP_0004157'>IAA</z:mp>) </plain></SENT>
<SENT sid="1" pm="."><plain>Within 5-10 days after initiation of Ig therapy the platelets of the children with <z:chebi fb="0" ids="16039">ITP</z:chebi> rose to 300,000-650,000/mm3 and could be maintained at <z:mpath ids='MPATH_458'>normal</z:mpath> levels with one Ig infusion every 1-3 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>No reaction was observed in the 2 patients with <z:mp ids='MP_0004157'>IAA</z:mp> </plain></SENT>
</text></document>